Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Admilparant in Pulmonary Fibrosis
NCT07441408Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2026
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of admilparant in pulmonary fibrosis (PF), sponsored by Bristol Myers Squibb. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
admilparant
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT07441408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441408.